David Krag

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/170018/publications.pdf

Version: 2024-02-01

115 papers	12,574 citations	47 h-index	111 g-index
		47006	23533
117 all docs	117 docs citations	117 times ranked	6949 citing authors

#	Article	IF	Citations
1	â€˜Refbinâ€™ an online platform to extract and classify large-scale information: a pilot study of COVID-19 related papers. BMJ Health and Care Informatics, 2022, 29, e100452.	3.0	1
2	Preparation of clinical-grade WBCs using leukocyte reduction filters. Journal of Immunological Methods, 2021, 499, 113157.	1.4	1
3	Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models. Clinical and Translational Oncology, 2020, 22, 1094-1104.	2.4	2
4	A cocktail of polyclonal affinity enriched antibodies against melanoma mutations increases binding and inhibits tumor growth. Journal of Immunological Methods, 2020, 478, 112720.	1.4	2
5	Characterization of sentinel node-derived antibodies from breast cancer patients. Journal of Immunological Methods, 2018, 455, 14-23.	1.4	4
6	Identification of tumor-reactive B cells and systemic IgG in breast cancer based on clonal frequency in the sentinel lymph node. Cancer Immunology, Immunotherapy, 2018, 67, 729-738.	4.2	42
7	Differential expression of Oct3/4 in human breast cancer and normal tissues. International Journal of Oncology, 2018, 52, 2069-2078.	3.3	13
8	Breast cancer metastasis through the lympho-vascular system. Clinical and Experimental Metastasis, 2018, 35, 443-454.	3.3	31
9	Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. Npj Breast Cancer, 2018, 4, 28.	5.2	20
10	Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses. Journal of Immunological Methods, 2018, 460, 51-62.	1.4	23
11	Vaccine draining lymph nodes are a source of antigen-specific B cells. Vaccine, 2017, 35, 1259-1265.	3.8	7
12	Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. Journal of Translational Medicine, 2017, 15, 180.	4.4	8
13	Internal mammary sentinel lymph node biopsy in clinical practice. International Journal of Surgery, 2016, 36, 332-334.	2.7	5
14	Autologous antibodies that bind neuroblastoma cells. Journal of Immunological Methods, 2015, 426, 35-41.	1.4	2
15	Identification of tumor-binding scFv derived from clonally related B cells in tumor and lymph node of a patient with breast cancer. Cancer Immunology, Immunotherapy, 2015, 64, 29-39.	4.2	12
16	Accuracy of sentinel node biopsy in esophageal carcinoma: a systematic review and meta-analysis of the pertinent literature. Surgery Today, 2014, 44, 607-619.	1.5	31
17	Axillary concordance between superficial and deep sentinel node mapping material injections in breast cancer patients: systematic review and meta-analysis of the literature. Breast Cancer Research and Treatment, 2014, 144, 213-222.	2.5	14
18	Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies. Cancer Immunology, Immunotherapy, 2013, 62, 1397-1410.	4.2	23

#	Article	IF	Citations
19	Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. Journal of Translational Medicine, 2013, 11, 242.	4.4	41
20	Single tumor imaging with multiple antibodies targeting different antigens. BioTechniques, 2012, 52, .	1.8	3
21	The Falseâ€Negative Rate of Sentinel Node Biopsy in Patients with Breast Cancer: A Metaâ€Analysis. World Journal of Surgery, 2012, 36, 2239-2251.	1.6	144
22	GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Research and Treatment, 2012, 133, 607-615.	2.5	46
23	Relationship Between Arm Morbidity and Patient-Reported Outcomes Following Surgery in Women with Node-Negative Breast Cancer: NSABP Protocol B-32. The Journal of Supportive Oncology, 2012, 11, 22-30.	2.3	12
24	Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. New England Journal of Medicine, 2011, 364, 412-421.	27.0	399
25	Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32.. Journal of Clinical Oncology, 2011, 29, 86-86.	1.6	0
26	Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32.. Journal of Clinical Oncology, 2011, 29, 80-80.	1.6	8
27	Phage-Displayed Combinatorial Peptide Libraries in Fusion to β-Lactamase as Reporter for an Accelerated Clone Screening: Potential Uses of Selected Enzyme-Linked Affinity Reagents in Downstream Applications. Combinatorial Chemistry and High Throughput Screening, 2010, 13, 75-87.	1.1	3
28	Use of SPR to Study the Interaction of G7-18NATE Peptide with the Grb7-SH2 Domain. International Journal of Peptide Research and Therapeutics, 2010, 16, 177-184.	1.9	13
29	Morbidity results from the NSABP Bâ€32 trial comparing sentinel lymph node dissection versus axillary dissection. Journal of Surgical Oncology, 2010, 102, 111-118.	1.7	387
30	Patient-Reported Outcomes in Sentinel Nodeâ€“Negative Adjuvant Breast Cancer Patients Receiving Sentinel-Node Biopsy or Axillary Dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32. Journal of Clinical Oncology, 2010, 28, 3929-3936.	1.6	131
31	Cancer cell-specific internalizing ligands from phage displayed Â-lactamase-peptide fusion libraries. Protein Engineering, Design and Selection, 2010, 23, 431-440.	2.1	14
32	Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 927-933.	10.7	1,477
33	Axillary Lymph Node Dissection. , 2010, , 505-517.		0
34	Current status of axillary lymph node dissection and sentinel node biopsy in breast cancer. Clinical Advances in Hematology and Oncology, 2010, 8, 471-3.	0.3	1
35	Surgeon Training, Protocol Compliance, and Technical Outcomes From Breast Cancer Sentinel Lymph Node Randomized Trial. Journal of the National Cancer Institute, 2009, 101, 1356-1362.	6.3	24
36	Phage-display selection on tumor histological specimens with laser capture microdissection. Journal of Immunological Methods, 2009, 347, 46-53.	1.4	20

#	Article	IF	Citations
37	Identification of single chain antibodies to breast cancer stem cells using phage display. Biotechnology Progress, 2009, 25, 1780-1787.	2.6	9
38	Quality Measures for Breast Cancer Surgery. Archives of Surgery, 2009, 144, 455.	2.2	54
39	Metastasis Detection in Sentinel Lymph Nodes: Comparison of a Limited Widely Spaced (NSABP) Tj ETQq1 1 0.784314 rgBT /Overloc Journal of Surgical Pathology, 2009, 33, 1583-1589.	3.7	58
40	Cytokeratin-positive Cells in the Bone Marrow of Breast Cancer Patients and Noncancer Donors. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 403-408.	1.2	3
41	Biopanning Phage-Display Libraries on Small Tissue Sections Captured by Laser Capture Microdissection. Journal of Biotech Research, 2009, 1, 55-63.	0.0	10
42	Is axillary dissection needed when the sentinal node is positive? Yes!. Journal of Surgical Oncology, 2008, 97, 197-198.	1.7	6
43	Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Research, 2008, 10, R69.	5.0	157
44	Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncology, The, 2007, 8, 881-888.	10.7	915
45	Design and synthesis of paclitaxel conjugated with an ErbB2â€recognizing peptide, ECâ€1. Biopolymers, 2007, 87, 225-230.	2.4	8
46	Towards a ligand targeted enzyme prodrug therapy: Single round panning of a Î²-lactamase scaffold library on human cancer cells. International Journal of Cancer, 2007, 120, 2233-2242.	5.1	8
47	Sentinel lymph node biopsy for breast cancer. Journal of Surgical Oncology, 2007, 96, 322-329.	1.7	20
48	Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. British Journal of Cancer, 2007, 96, 1520-1525.	6.4	65
49	Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opinion on Biological Therapy, 2006, 6, 39-54.	3.1	19
50	Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. Cancer, 2006, 107, 661-667.	4.1	35
51	Specific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis. Journal of the National Cancer Institute, 2006, 98, 491-498.	6.3	84
52	Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries. Cancer Research, 2006, 66, 7724-7733.	0.9	179
53	The Detection of Isolated Tumor Cells in Bone Marrow Comparing Bright-Field Immunocytochemistry and Multicolor Immunofluorescence. Annals of Surgical Oncology, 2005, 12, 753-760.	1.5	8
54	Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 Trial. Annals of Surgery, 2005, 241, 48-54.	4.2	105

#	Article	IF	Citations
55	A Sensitive and Rapid Chemiluminescence ELISA for Filamentous Bacteriophages. Journal of Immunoassay and Immunochemistry, 2005, 26, 89-95.	1.1	13
56	Phage display selection for cell-specific ligands: Development of a screening procedure suitable for small tumor specimens. Journal of Drug Targeting, 2005, 13, 7-18.	4.4	42
57	Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library. Oncology Reports, 2005, 13, 757-64.	2.6	37
58	Breast cancer and the NSABP-B32 sentinel node trial. Breast Cancer, 2004, 11, 221-224.	2.9	14
59	NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial. Annals of Surgical Oncology, 2004, 11, 208S-210S.	1.5	51
60	Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. International Journal of Cancer, 2004, 111, 951-960.	5.1	43
61	NSABP-32: Phase III, Randomized Trial Comparing Axillary Resection with Sentinal Lymph Node Dissection: A Description of the Trial. Annals of Surgical Oncology, 2004, 11, 208S-210S.	1.5	100
62	Lymphoscintigraphy and Sentinel Node Biopsy Accurately Stage Melanoma in Patients Presenting After Wide Local Excision. Annals of Surgical Oncology, 2003, 10, 416-425.	1.5	33
63	Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. British Journal of Haematology, 2003, 120, 109-116.	2.5	61
64	Comparison of Pathologist-Detected and Automated Computer-Assisted Image Analysis Detected Sentinel Lymph Node Micrometastases in Breast Cancer. Modern Pathology, 2003, 16, 1159-1163.	5.5	55
65	Breast Cancer Survival According to Number of Nodes Removed. Annals of Surgical Oncology, 2003, 10, 1152-1159.	1.5	86
66	Current status of sentinel node surgery in breast cancer. Oncology, 2003, 17, 1663-6; discussion 1669-70, 1675-6.	0.5	3
67	Identification of Novel Non-phosphorylated Ligands, Which Bind Selectively to the SH2 Domain of Grb7. Journal of Biological Chemistry, 2002, 277, 11918-11926.	3.4	87
68	Pathological and molecular assessment of sentinel lymph nodes in solid tumors. Seminars in Oncology, 2002, 29, 274-279.	2.2	25
69	Phage-displayed random peptide libraries in mice: toxicity after serial panning. Cancer Chemotherapy and Pharmacology, 2002, 50, 325-332.	2.3	24
70	Why perform randomized clinical trials for sentinel node surgery for breast cancer?. American Journal of Surgery, 2001, 182, 411-413.	1.8	26
71	Sentinel Lymph Node Biopsy in Breast Cancer. Breast Disease, 2001, 12, 43-55.	0.8	5
72	Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Research, 2001, 11, 45-55.	1.2	71

#	Article	IF	Citations
73	Radiolabeled Sentinel Node Biopsy: Collaborative Trial with the National Cancer Institute. World Journal of Surgery, 2001, 25, 823-828.	1.6	42
74	Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed?. Annals of Surgical Oncology, 2001, 8, 192-197.	1.5	258
75	Sentinel lymph node?why study it: Implications of the B-32 study. Journal of Surgical Oncology, 2001, 20, 224-229.	1.4	29
76	Tamoxifen and Cardiac Risk Factors in Healthy Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 255-261.	2.4	85
77	Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed?. Annals of Surgical Oncology, 2001, 8, 192-197.	1.5	2
78	Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma. Cancer, 2000, 88, 1099-1107.	4.1	199
79	The Augsburg consensus. Cancer, 2000, 89, 236-241.	4.1	186
80	Sentinel Lymph Node Radiolocalization in Head and Neck Squamous Cell Carcinoma. Laryngoscope, 2000, 110, 198-198.	2.0	142
81	Intrusive thoughts and avoidance in breast cancer: Individual differences and association with psychological distress. Psychology and Health, 2000, 14, 1141-1153.	2.2	40
82	Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma. Cancer, 2000, 88, 1099-1107.	4.1	3
83	The Augsburg consensus. Cancer, 2000, 89, 236-241.	4.1	5
84	Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer, 2000, 88, 1099-107.	4.1	34
85	Adjustment to breast cancer: ageâ€related differences in coping and emotional distress. Breast Cancer Research and Treatment, 1999, 54, 195-203.	2.5	114
86	Extra-axillary sentinel lymph nodes in breast cancer. Breast Cancer, 1999, 6, 159-165.	2.9	28
87	The sentinel node for staging breast cancer: Current review. Breast Cancer, 1999, 6, 233-236.	2.9	31
88	Guidelines for the Safe Use of Radioactive Materials During Localization and Resection of the Sentinel Lymph Node. Annals of Surgical Oncology, 1999, 6, 75-82.	1.5	82
89	Unfiltered Sulfur Colloid and Sentinel Node Biopsy for Breast Cancer: Technical and Kinetic Considerations. Annals of Surgical Oncology, 1999, 6, 746-755.	1.5	41
90	Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. Journal of the American College of Surgeons, 1999, 188, 248-254.	0.5	139

#	Article	IF	Citations
91	Intraoperative ultrasound localization to guide surgical excision of nonpalpable breast carcinoma11No competing interests declared.. Journal of the American College of Surgeons, 1999, 189, 241-246.	0.5	132
92	Breast Cancer Cells in the Blood: A Pilot Study. Breast Journal, 1999, 5, 354-358.	1.0	64
93	Psychological adjustment in breast cancer: Processes of emotional distress.. Health Psychology, 1999, 18, 315-326.	1.6	143
94	Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patient eligibility. American Surgeon, 1999, 65, 493-8; discussion 498-9.	0.8	46
95	Radiolocalization of the sentinel lymph node in Merkel cell carcinoma: A clinical analysis of seven cases. , 1998, 67, 251-254.		55
96	Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Annals of Surgical Oncology, 1998, 5, 689-694.	1.5	157
97	Ultrasonographically guided injection improves localization of the radiolabeled sentinel lymph node in breast cancer. Annals of Surgical Oncology, 1998, 5, 315-321.	1.5	75
98	Development of Sentinel Node Targeting Technique in Breast Cancer Patients. Breast Journal, 1998, 4, 67-74.	1.0	105
99	Sentinel lymph node biopsy for melanoma. American Journal of Surgery, 1998, 176, 544-547.	1.8	49
100	Sentinel lymph node biopsy for staging breast cancer. American Journal of Surgery, 1998, 176, 532-537.	1.8	98
101	Minimal access surgery for staging regional lymph nodes: The sentinel-node concept. Current Problems in Surgery, 1998, 35, 951-1016.	1.1	52
102	The Sentinel Node in Breast Cancer â€" A Multicenter Validation Study. New England Journal of Medicine, 1998, 339, 941-946.	27.0	1,907
103	Transport and retention of colloidal tracers in regional lymphoscintigraphy in melanoma: influence on lymphatic mapping and sentinel node biopsy. Melanoma Research, 1998, 8, 413-418.	1.2	26
104	Sentinel lymph node localization in early breast cancer. Journal of Nuclear Medicine, 1998, 39, 1388-93.	5.0	53
105	Nonphosphorylated Peptide Ligands for the Grb2 Src Homology 2 Domain. Journal of Biological Chemistry, 1997, 272, 29046-29052.	3.4	98
106	The gamma-probe-guided resection of radiolabeled primary lymph nodes. Surgical Oncology Clinics of North America, 1996, 5, 33-41.	1.5	38
107	Gamma-probe-guided lymph node localization in malignant melanoma. Surgical Oncology, 1993, 2, 303-308.	1.6	304
108	Gamma-probe guided localization of lymph nodes. Surgical Oncology, 1993, 2, 137-143.	1.6	346

#	Article	IF	Citations
109	Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surgical Oncology, 1993, 2, 335-340.	1.6	1,464
110	Clinical Assessment of 111In-CYT-103 Immunoscintigraphy in Ovarian Cancer. Gynecologic Oncology, 1993, 48, 285-292.	1.4	51
111	Intratumoral chemotherapy with cisplatin in oily emulsion in horses. Journal of the American Veterinary Medical Association, 1993, 202, 261-7.	0.5	91
112	Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.. Radiology, 1992, 185, 179-186.	7.3	119
113	A simplified technique to resect abnormal bony radiolocalizations using a gamma counter. Surgical Oncology, 1992, 1, 371-377.	1.6	19
114	Gamma probe location of111 indium-labeled B72.3: An extension of immunoscintigraphy. Journal of Surgical Oncology, 1992, 51, 226-230.	1.7	24
115	Radiolabeled Antibody Imaging in the Management of Colorectal Cancer Results of a Multicenter Clinical Study. Annals of Surgery, 1991, 214, 118-124.	4.2	115